AU3895299A - Use of anti-prolactin agents to treat proliferative conditions - Google Patents

Use of anti-prolactin agents to treat proliferative conditions

Info

Publication number
AU3895299A
AU3895299A AU38952/99A AU3895299A AU3895299A AU 3895299 A AU3895299 A AU 3895299A AU 38952/99 A AU38952/99 A AU 38952/99A AU 3895299 A AU3895299 A AU 3895299A AU 3895299 A AU3895299 A AU 3895299A
Authority
AU
Australia
Prior art keywords
prolactin
proliferative conditions
treat proliferative
agents
prolactin agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38952/99A
Other languages
English (en)
Inventor
Wen Y Chen
Thomas E. Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26772335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3895299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU3895299A publication Critical patent/AU3895299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU38952/99A 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions Abandoned AU3895299A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8512898P 1998-05-12 1998-05-12
US60085128 1998-05-12
US24604199A 1999-02-05 1999-02-05
US09246041 1999-02-05
PCT/US1999/010232 WO1999058142A1 (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Publications (1)

Publication Number Publication Date
AU3895299A true AU3895299A (en) 1999-11-29

Family

ID=26772335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38952/99A Abandoned AU3895299A (en) 1998-05-12 1999-05-11 Use of anti-prolactin agents to treat proliferative conditions

Country Status (11)

Country Link
US (2) US7115556B2 (https=)
EP (2) EP1079851B1 (https=)
JP (4) JP5259896B2 (https=)
AT (1) ATE366114T1 (https=)
AU (1) AU3895299A (https=)
CA (1) CA2328520C (https=)
DE (1) DE69936451T2 (https=)
DK (1) DK1079851T3 (https=)
ES (1) ES2288777T3 (https=)
PT (1) PT1079851E (https=)
WO (1) WO1999058142A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
ES2346304T3 (es) * 2002-06-12 2010-10-14 L'oreal Composicion cosmetica de cuidado y/o maquillaje estructurada con polimeros de silicona y agentes organogelificantes, en forma rigida.
WO2004054516A2 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US8754031B2 (en) * 2004-03-08 2014-06-17 Oncolix, Inc. Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
US7507716B2 (en) * 2005-07-06 2009-03-24 Board Of Regents, The University Of Texas System Method for treating pain with prolactin antagonists
WO2008028684A2 (en) * 2006-09-08 2008-03-13 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2008114077A1 (en) * 2007-03-20 2008-09-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Constitutively active mutants of the prolactin receptor
WO2009003732A2 (en) * 2007-07-05 2009-01-08 Novo Nordisk A/S Peptides with high affinity for the prolactin receptor
WO2009135056A2 (en) * 2008-04-30 2009-11-05 Monsanto Technology Llc Recombinant dna vectors for expression of human prolactin antagonists
US8648046B2 (en) 2009-02-26 2014-02-11 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
EP2400979B1 (en) * 2009-02-26 2015-05-20 Oncolix, Inc. Compositions and methods for visualizing and eliminating cancer stem cells
US8759289B2 (en) * 2010-02-03 2014-06-24 Orbis Health Solutions Llc Method for sensitizing cancer stem cells to cancer therapy
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833516A (en) * 1987-08-03 1989-05-23 International Business Machines Corporation High density memory cell structure having a vertical trench transistor self-aligned with a vertical trench capacitor and fabrication methods therefor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
DE4231297A1 (de) 1992-09-18 1994-03-24 Basf Ag Verfahren zur Herstellung von 3-(2'-Oxyethyl)-dihydro-2-(3H)furanonen
WO1994019004A1 (en) 1993-02-19 1994-09-01 Genentech, Inc. Ligand antagonists for treatment of breast cancer
DK0754682T3 (da) * 1994-04-06 2002-02-04 Western Therapeutics Inst D Aminostilbazolderivat og lægemiddel
DE19718721C2 (de) * 1997-05-02 1999-10-07 Siemens Ag DRAM-Zellenanordnung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
JP2011079821A (ja) 2011-04-21
EP1079851A1 (en) 2001-03-07
ATE366114T1 (de) 2007-07-15
WO1999058142A1 (en) 1999-11-18
US7115556B2 (en) 2006-10-03
ES2288777T3 (es) 2008-01-16
PT1079851E (pt) 2007-10-08
EP2316467A1 (en) 2011-05-04
US20070060520A1 (en) 2007-03-15
DK1079851T3 (da) 2007-09-24
EP1079851B1 (en) 2007-07-04
WO1999058142A9 (en) 2000-02-10
DE69936451D1 (de) 2007-08-16
JP2012020996A (ja) 2012-02-02
EP1079851A4 (en) 2004-03-17
JP5259896B2 (ja) 2013-08-07
CA2328520A1 (en) 1999-11-18
JP2013224309A (ja) 2013-10-31
CA2328520C (en) 2013-06-25
JP5453355B2 (ja) 2014-03-26
JP2002515404A (ja) 2002-05-28
DE69936451T2 (de) 2008-03-13
US20030022833A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
AU3895299A (en) Use of anti-prolactin agents to treat proliferative conditions
IL146482A0 (en) Tek antagonists
AP1869A (en) b2- Adrenergic receptor agonists.
WO2001045730A3 (en) Tweak receptor
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
YU42302A (sh) Agonisti beta2-adrenergičnih receptora
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
SI1556058T1 (sl) Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
BG105534A (en) 5ht1 means and method for the treatment of migraine
CZ2000531A3 (en) Method of prevention or therapy of estrogen-dependent diseases and disorders
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
PL344304A1 (en) Combination therapy for treatment of bipolar disorders
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
CA2245766A1 (en) Compositions useful in the phototherapeutic treatment of proliferative skin disorders
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2002079235A3 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase